Liraglutide attenuates type 2 diabetes mellitus-associated non-alcoholic fatty liver disease by activating AMPK/ACC signaling and inhibiting ferroptosis

Liraglutide attenuates type 2 diabetes mellitus-associated non-alcoholic fatty liver disease by activating AMPK/ACC signaling and inhibiting ferroptosis

Abstract Background Non-alcoholic fatty liver disease (NAFLD) is one of the most common complications of type 2 diabetes mellitus (T2DM). The pathogenesis of NAFLD involves multiple biological changes, including insulin resistance, oxidative stress, inflammation, as well as genetic and environmental...

Full description

Bibliographic Details
Main Authors: Tingli Guo, Wenhui Yan, Xin Cui, Na Liu, Xiaotong Wei, Yuzhuo Sun, KeXin Fan, Jieyun Liu, Yuanyuan Zhu, Zhuanzhuan Wang, Yilei Zhang, Lina Chen
Format: Article
Language:English
Published: BMC 2023-09-01
Series:Molecular Medicine
Subjects:
Liraglutide
Type 2 diabetes mellitus
Non-alcoholic fatty liver disease
Lipid peroxidation
Ferroptosis
Online Access:https://doi.org/10.1186/s10020-023-00721-7

Internet

https://doi.org/10.1186/s10020-023-00721-7

Similar Items